Nexenzymes provides high‑performance enzymatic solutions for diagnostics and biotechnology, producing them locally in Latin America while meeting global quality standards. Their platform combines custom enzyme engineering with AI‑driven optimization, enabling laboratories to shorten development cycles and receive shipments within 72 hours, eliminating long import delays. By fostering regional biotech sovereignty, they support the development of microbiome‑based therapies and metabolic disease treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Biotech laboratories in Latin America face long import times, high inventory costs, and limited access to high‑quality enzymatic reagents, slowing diagnostic development and therapeutic research.
Solution
Nexenzymes produces high‑performance enzymes locally in Latin America while adhering to global quality standards. An AI‑driven platform customizes master mixes, reducing assay optimization time by up to 70%. The company offers rapid 72‑hour delivery, eliminating the need for large inventory buffers and enabling faster R&D cycles. By providing locally sourced, precision reagents, Nexenzymes supports a self‑sustaining biotech ecosystem and accelerates development of microbiome‑based therapies and metabolic disease treatments.
Target Audience
Primary customers are diagnostic developers, biotech research labs, and pharmaceutical teams in Latin America that require fast, reliable enzymatic reagents for assay development and therapeutic pipelines.
Features
- AI‑based formulation tool that tailors enzyme master mixes to specific assay requirements
- Locally manufactured enzymes meeting international purity and activity specifications
- 72‑hour on‑demand shipping to laboratories across Latin America
- Scalable production capacity that reduces reliance on imported reagents
- Compatibility with a wide range of diagnostic and biotechnology workflows